Obesity

Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and Mortality

JAMA Netw OpenPublished Retrospective cohort study

Authors' conclusion

In this cohort study, BMS was associated with greater reduced mortality compared with first-generation GLP-1RAs among individuals with a diabetes duration of 10 years or less, mediated via greater weight loss. No differences in the risk for mortality were observed between the treatment modalities among individuals with a longer duration of diabetes, nor in the occurrence of nonfatal MACEs among all patients.

Study context

Population
Adults aged ≥24 years with diabetes and obesity and no prior ischemic heart disease, ischemic stroke or congestive HF, Clalit Health Services, Israel (2008–2021); mean age 51.0 years, 64.9% women
Participants
6,070 adults3,035 matched pairs
Exposure
Bariatric metabolic surgery (BMS) vs GLP-1 RA
Outcome
All-cause mortality
Follow-up
Median 6.8 years (IQR, 4.1-9.4 years)
Methodological detailsobservational, matched 1:1 by age, sex and clinical characteristics
  • Observational
  • Matched 1:1 by age, sex and clinical characteristics

Main finding

As reported in the abstract

BMS vs GLP-1RAsHazard ratio (95% CI)
Diabetes duration ≤10 years (2371 pairs)
0.38(0.25–0.58)
Diabetes duration ≤10 years, model including weight loss; nonsignificant
0.79(0.43–1.48)
Diabetes duration >10 years (664 pairs); no survival advantage
0.65(0.39–1.08)

Observational data: associations, not effects.

Secondary outcomes

OutcomeHR (95% CI)
Nonfatal MACEBMSvs GLP-1RAsDiabetes duration ≤10 years · multivariate competing risk models0.74 (0.49–1.10)
Nonfatal MACEBMSvs GLP-1RAsDiabetes duration >10 years · multivariate competing risk models1.21 (0.80–1.85)

Nonfatal MACE

Risk of nonfatal MACE did not differ between the treatment groups

Original publication

Bariatric Metabolic Surgery vs Glucagon-Like Peptide-1 Receptor Agonists and Mortality. JAMA Netw Open. Published 3 June 2024. doi:10.1001/jamanetworkopen.2024.15392

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.